전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Research article


References

  1. Bode L. 2012. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22: 1147-1162.
    Pubmed PMC CrossRef
  2. Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, et al. 2006. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediat. Res. 59: 377-382.
    Pubmed CrossRef
  3. Thurl S, Munzert M, Henker J, Boehm G, Mller-Werner B, Jelinek J, et al. 2010. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. Br. J. Nutr. 104: 1261-1271.
    Pubmed CrossRef
  4. Smith-Brown P, Morrison M, Krause L, Davies PSW. 2016. Mothers secretor status affects development of childrens microbiota composition and function: a pilot study. PLoS One 11: e0161211.
    Pubmed PMC CrossRef
  5. Han NS, Kim TJ, Park YC, Kim J, Seo JH. 2012. Biotechnological production of human milk oligosaccharides. Biotechnol. Adv. 30: 1268-1278.
    Pubmed CrossRef
  6. Li C, Wu M, Gao X, Zhu ZL, Li Y, Lu FP, et al. 2020. Efficient biosynthesis of 2'-fucosyllactose using an in vitro multienzyme cascade. J. Agr. Food Chem. 68: 10763-10771.
    Pubmed CrossRef
  7. Lee HJ, Shin DJ, Han K, Chin YW, Park JP, Park K, et al. 2022. Simultaneous production of 2'-fucosyllactose and difucosyllactose by engineered Escherichia coli with high secretion efficiency. Biotechnol. J. 17: e2100629.
    Pubmed CrossRef
  8. Shin J, Jin YS, Park YC, Park JB, Lee YO, Kim SK, et al. 2021. Enhancing acid tolerance of Escherichia coli via viroporin-mediated export of protons and its application for efficient whole-cell biotransformation. Metab. Eng. 67: 277-284.
    Pubmed CrossRef
  9. Yu S, Liu JJ, Yun EJ, Kwak S, Kim KH, Jin YS. 2018. Production of a human milk oligosaccharide 2'-fucosyllactose by metabolically engineered Saccharomyces cerevisiae. Microb. Cell Fact. 17: 101.
    Pubmed PMC CrossRef
  10. Liu TW, Ito H, Chiba Y, Kubota T, Sato T, Narimatsu H. 2011. Functional expression of L-fucokinase/guanosine 5'-diphosphate-Lfucose pyrophosphorylase from Bacteroides fragilis in Saccharomyces cerevisiae for the production of nucleotide sugars from exogenous monosaccharides. Glycobiology 21: 1228-1236.
    Pubmed CrossRef
  11. Chin YW, Kim JY, Lee WH, Seo JH. 2015. Enhanced production of 2'-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase. J. Biotechnol. 210: 107-115.
    Pubmed CrossRef
  12. Park Y, Shin J, Yang J, Kim H, Jung Y, Oh H, et al. 2020. Plasmid display for stabilization of enzymes inside the cell to improve wholecell biotransformation efficiency. Front. Bioeng. Biotechnol. 7: 444.
    Pubmed PMC CrossRef
  13. Ren J, Hwang S, Shen J, Kim H, Kim H, Kim J, et al. 2022. Enhancement of the solubility of recombinant proteins by fusion with a short-disordered peptide. J. Microbiol. 60: 960-967.
    Pubmed CrossRef
  14. Mamipour M, Yousefi M, Hasanzadeh M. 2017. An overview on molecular chaperones enhancing solubility of expressed recombinant proteins with correct folding. Int. J. Biol. Macromol. 102: 367-375.
    Pubmed PMC CrossRef
  15. Wang T, Badran AH, Huang TP, Liu DR. 2018. Continuous directed evolution of proteins with improved soluble expression. Nat. Chem. Biol. 14: 972-980.
    Pubmed PMC CrossRef
  16. Reyes LH, Cardona C, Pimentel L, Rodriguez-Lopez A, Almeciga-Diaz CJ. 2017. Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches. Sci. Rep. 7: 5844.
    Pubmed PMC CrossRef
  17. Han X, Ning W, Ma X, Wang X, Zhou K. 2020. Improving protein solubility and activity by introducing small peptide tags designed with machine learning models. Metab. Eng. Commun. 11: e00138.
    Pubmed PMC CrossRef
  18. Kim C, Park M, Yang J, Shin J, Park YC, Kim SK, et al. 2021. Inducible plasmid display system for high-throughput selection of proteins with improved solubility. J. Biotechnol. 329: 143-150.
    Pubmed CrossRef
  19. Wang H, Wang L, Zhong BH, Dai ZJ. 2022. Protein splicing of inteins: a powerful tool in synthetic biology. Front. Bioeng. Biotechnol. 10: 810180.
    Pubmed PMC CrossRef
  20. ang J, Kim N, Park W, Chun J, Kim S, Shin J, et al. 2022. Optimization of protein trans-splicing in an inducible plasmid display system for high-throughput screening and selection of soluble proteins. Enzyme Microb. Technol. 153: 109914.
    Pubmed CrossRef
  21. Li CK, Wen AY, Shen BC, Lu J, Huang Y, Chang YC. 2011. FastCloning: a highly simplified, purification-free, sequence- and ligationindependent PCR cloning method. BMC Biotechnol. 11: 92.
    Pubmed PMC CrossRef
  22. Lee WH, Han NS, Park YC, Seo JH. 2009. Modulation of guanosine 5'-diphosphate-D-mannose metabolism in recombinant Escherichia coli for production of guanosine 5'-diphosphate-L-fucose. Bioresour. Technol. 100: 6143-6148.
    Pubmed CrossRef
  23. Baig F, Fernando LP, Salazar MA, Powell RR, Bruce TF, Harcum SW. 2014. Dynamic transcriptional response of Escherichia coli to inclusion body formation. Biotechnol. Bioeng. 111: 980-999.
    Pubmed PMC CrossRef
  24. Packer MS, Liu DR. 2015. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16: 379-394.
    Pubmed CrossRef
  25. Hart DJ, Tarendeau F. 2006. Combinatorial library approaches for improving soluble protein expression in Escherichia coli. Acta Crystallogr. D 62: 19-26.
    Pubmed CrossRef
  26. Ren C, Wen X, Mencius J, Quan S. 2019. Selection and screening strategies in directed evolution to improve protein stability. Bioresour. Bioprocess 6: 53.
    CrossRef
  27. Daunert S, Barrett G, Feliciano JS, Shetty RS, Shrestha S, Smith-Spencer W. 2000. Genetically engineered whale-cell sensing systems: coupling biological recognition with reporter genes. Chem. Rev. 100: 2705-2738.
    Pubmed CrossRef
  28. Janocha S, Bichet A, Zollner A, Bernhardt R. 2011. Substitution of lysine with glutamic acid at position 193 in bovine CYP11A1 significantly affects protein oligomerization and solubility but not enzymatic activity. Biochim. Biophys. Acta 1814: 126-131.
    Pubmed CrossRef
  29. Seitz T, Bocola M, Claren J, Sterner R. 2007. Stabilisation of a (βα)8-barrel protein designed from identical half barrels. J. Mol. Biol. 372: 114-129.
    Pubmed CrossRef
  30. Behar G, Sole V, Defontaine A, Maillasson M, Quemener A, Jacques Y, et al. 2011. Evolution of interleukin-15 for higher E. coli expression and solubility. Protein Eng. Des. Sel. 24: 283-290.
    Pubmed CrossRef
  31. Rodriguez-Banqueri A, Errasti-Murugarren E, Bartoccioni P, Kowalczyk L, Peralvarez-Marin A, Palacin M, et al. 2016. Stabilization of a prokaryotic LAT transporter by random mutagenesis. J. Gen. Physiol. 147: 353-368.
    Pubmed PMC CrossRef
  32. Mo HM, Xu Y, Yu XW. 2018. Improved soluble expression and catalytic activity of a thermostable esterase using a high-throughput screening system based on a split-GFP assembly. J. Agr. Food Chem. 66: 12756-12764.
    Pubmed CrossRef
  33. Biswas T, Houghton JL, Garneau-Tsodikova S, Tsodikov OV. 2012. The structural basis for substrate versatility of chloramphenicol acetyltransferase CATI. Protein Sci. 21: 520-530.
    Pubmed PMC CrossRef
  34. Wright GD, Thompson PR. 1999. Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Front. Biosci. 4: D9-21.
    CrossRef
  35. Tokuriki N, Stricher F, Serrano L, Tawfik DS. 2008. How protein stability and new functions trade off. PLoS Comput. Biol. 4: e1000002.
    Pubmed PMC CrossRef
  36. Wang XJ, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320: 85-95.
    Pubmed CrossRef
  37. DePristo MA, Weinreich DM, Hartl DL. 2005. Missense meanderings in sequence space: a biophysical view of protein evolution. Nat. Rev. Genet. 6: 678-687.
    Pubmed CrossRef
  38. Studer RA, Christin PA, Williams MA, Orengo CA. 2014. Stability-activity tradeoffs constrain the adaptive evolution of RubisCO. Proc. Natl. Acad. Sci. USA 111: 2223-2228.
    Pubmed PMC CrossRef
  39. Tokuriki N, Tawfik DS. 2009. Stability effects of mutations and protein evolvability. Curr. Opin. Struc. Biol. 19: 596-604.
    Pubmed CrossRef
  40. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596: 583-589.
    Pubmed PMC CrossRef
  41. Jung SY, Park SS. 2008. Improving the expression yield of Candida antarctica lipase B in Escherichia coli by mutagenesis. Biotechnol. Lett. 30: 717-722.
    Pubmed CrossRef
  42. Massey-Gendel E, Zhao A, Boulting G, Kim HY, Balamotis MA, Seligman LM, et al. 2009. Genetic selection system for improving recombinant membrane protein expression in E. coli. Protein Sci. 18: 372-383.
    Pubmed PMC CrossRef

Related articles in JMB

More Related Articles

Article

Research article

J. Microbiol. Biotechnol. 2022; 32(11): 1471-1478

Published online November 28, 2022 https://doi.org/10.4014/jmb.2209.09018

Copyright © The Korean Society for Microbiology and Biotechnology.

Directed Evolution of Soluble α-1,2-Fucosyltransferase Using Kanamycin Resistance Protein as a Phenotypic Reporter for Efficient Production of 2'-Fucosyllactose

Jonghyeok Shin1,2†, Seungjoo Kim1†, Wonbeom Park1, Kyoung Chan Jin3, Sun-Ki Kim3*, and Dae-Hyuk Kweon1*

1Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seoburo 2066, Suwon, Gyeonggi 16419, Republic of Korea
2Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
3Department of Food Science and Technology, Chung-Ang University, Anseong, Gyeonggi 17546, Republic of Korea

Correspondence to:Sun-Ki Kim,       skkim18@cau.ac.kr
Dae-Hyuk Kweon,      dhkweon@skku.edu

These authors contributed equally to this paper.

Received: September 13, 2022; Revised: October 11, 2022; Accepted: October 12, 2022

Abstract

2'-Fucosyllactose (2'-FL), the most abundant fucosylated oligosaccharide in human milk, has multiple beneficial effects on human health. However, its biosynthesis by metabolically engineered Escherichia coli is often hampered owing to the insolubility and instability of α-1,2-fucosyltransferase (the rate-limiting enzyme). In this study, we aimed to enhance 2'-FL production by increasing the expression of soluble α-1,2-fucosyltransferase from Helicobacter pylori (FucT2). Because structural information regarding FucT2 has not been unveiled, we decided to improve the expression of soluble FucT2 in E. coli via directed evolution using a protein solubility biosensor that links protein solubility to antimicrobial resistance. For such a system to be viable, the activity of kanamycin resistance protein (KanR) should be dependent on FucT2 solubility. KanR was fused to the C-terminus of mutant libraries of FucT2, which were generated using a combination of error-prone PCR and DNA shuffling. Notably, one round of the directed evolution process, which consisted of mutant library generation and selection based on kanamycin resistance, resulted in a significant increase in the expression level of soluble FucT2. As a result, a batch fermentation with the ΔL M15 pBCGW strain, expressing the FucT2 mutant (F#1–5) isolated from the first round of the directed evolution process, resulted in the production of 0.31 g/l 2'-FL with a yield of 0.22 g 2'-FL/g lactose, showing 1.72- and 1.51-fold increase in the titer and yield, respectively, compared to those of the control strain. The simple and powerful method developed in this study could be applied to enhance the solubility of other unstable enzymes.

Keywords: 2&prime,-fucosyllactose, &alpha,-1,2-fucosyltransferase, directed evolution, solubility biosensor, kanamycin resistance, Escherichia coli

Introduction

Human milk oligosaccharides (HMOs) have multiple beneficial functions, such as the regulation of the human immune system and protection against pathogens, including viruses, bacteria, and protozoa [1]. Among the various oligosaccharides present in HMOs, 2'-fucosyllactose (Fuc-α1,2-Gal-β1,4-Glc; 2'-FL) is highly abundant and has attracted great interest as a functional food ingredient because of its pharmaceutical and nutraceutical properties [2, 3]. However, the milk of some women (non-secretor) does not contain 2'-FL owing to genetic variation [4].

A biosynthetic approach based on in vitro enzymatic reactions or metabolically engineered microorganisms is commonly considered an efficient and sustainable method for producing 2'-FL on a large scale [5]. Since in vitro multienzyme catalysis requires purified reagents and enzymes that increase production costs, production of 2'-FL using engineered microbes has been proven to be cost effective [5, 6]. In engineered Escherichia coli [7, 8] and Saccharomyces cerevisiae [9, 10] capable of producing 2'-FL, lactose is fucosylated by a heterologous α-1,2-fucosyltransferase using guanosine 5'‐diphosphate (GDP)-L-fucose as a fucose donor. However, despite several attempts to construct high-performance strains, the 2'-FL titers are often reported to be low because of the insoluble and unstable nature of α-1,2-fucosyltransferase under process conditions [11, 12].

Fusion protein technologies [13], chaperone co-expression [14], directed evolution [15], promoter optimization [16], and machine learning [17] have been used to improve solubility of target proteins. We previously developed an inducible plasmid display system to improve the solubility of α-1,2-fucosyltransferase from Helicobacter pylori (FucT2) [18]. In this system, the C-terminal end of FucT2 and the N-terminal end of Oct-1 DNA-binding domain were fused to the N-terminal and C-terminal domains of an intein, respectively. Inteins are protein segments capable of mediating protein trans-splicing, which refers to the ligation of flanking extein into a new protein [19]. The efficiency of protein trans-splicing and FucT2 display on a plasmid were designed to be dependent on FucT2 solubility. However, soluble FucT2 mutants with improved activity were not obtained, mainly because the efficiency of FucT2 display on a plasmid was primarily dependent on induction time and expression levels of protein trans-splicing domains [18, 20].

To overcome this limitation, we used a biosensor that links protein solubility to antimicrobial resistance. For such a system to be viable, the antibiotic resistance of cells containing the biosensor should be directly correlated with FucT2 solubility. To this end, aminoglycoside-3'-phosphotransferase (i.e., kanamycin resistance protein) was fused to the C-terminus of the mutant libraries of FucT2 (Fig. 1). In this system, the biosensor is rendered non-functional when FucT2 mutants are expressed in an insoluble form, rendering the cells containing the corresponding constructs susceptible to kanamycin. In contrast, soluble FucT2 mutants confer high levels of kanamycin resistance to cells.

Figure 1. A schematic diagram representing overall process of directed evolution. FucT2 mutant libraries were generated via a combination of error-prone PCR and DNA shuffling. The expression of the fusion protein (FucT2-KanR) consisting of FucT2 and kanamycin (Kan) resistance protein (KanR) was under the transcriptional control of the PBAD promoter. The amino acid sequence of the linker was KSAAGT. Kan-resistant E. coli Top10 cells expressing FucT2-KanR were isolated from solid LB medium containing 2 g/l L-arabinose and 10–200 μg/ml Kan. Finally, the solubility and activity of FucT2 mutants were characterized, or they were used as substrates for the next round of evolution.

In this study, a protein solubility-based selection strategy for directed evolution was developed to allow for a high-throughput analysis of complex libraries within a short time and to enhance 2'-FL production in recombinant E. coli.

Materials and Methods

Strains and Plasmids

All the strains and plasmids used in this study are listed in Table 1. E. coli TOP10 was used for genetic manipulation and directed evolution of FucT2, and E. coli ΔL M15 [11] was used for 2'-FL production. A ligase-independent molecular cloning method was used [21]. To construct pSel2-FucT2, pSel2-FucT2 I and pSel2-FucT2 V primers were used to amplify the coding sequence of FucT2 and linearize the plasmid pSel2 (Addgene, USA), respectively. After the DNA fragments of the vector and the insert were amplified using Pfu polymerase (Elpis-Biotech, Daejeon, Korea), they were ligated using T4 DNA polymerase (New England Biolabs, USA).

Table 1 . Escherichia coli strains and plasmids used in this study..

NameDescriptionReference
E. coli
TOP10F mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupGInvitrogen (USA)
ΔL M15BL21 star (DE3) ΔlacZYA Tn7::lacZΔM15[11]
Plasmids
pSel2PBAD promoter-KanR expression system, ColEI origin, AmpR[42]
pSel2-FucT2pSel2 + wild type FucT2This study
pSel2-FucT2mutpSel2 + FucT2 mutantsThis study
pColAduet-1Two T7 promoters, ColA origin, KanRNovagen (Germany)
pColAduet-FucT2pColAduet + wild type FucT2 from H. pyloriAP Technology (Republic of Korea)
pColAduet-FucT2mutpColAduet + FucT2 mutantsThis study


pColAduet-FucT2 and pColAduet-FucT2mut plasmids were designed to contain the genes encoding wild-type (WT) FucT2 and its mutants, respectively, for production of 2'-FL in E. coli. To construct pColAduet-FucT2mut, pColAduet-FucT2 I and pColAduet-FucT2 V primers were used to amplify the coding sequence of FucT2 and to linearize the plasmid pColAduet-1 (Novagen, Germany), respectively. The two DNA fragments were amplified and ligated as described above. The primers used for plasmid construction are listed in Table S1.

Kanamycin Sensitivity Assay

E. coli TOP10 harboring pSel2 or pSel2-FucT2 was precultured overnight at 37°C and 200 ×g in Luria–Bertani (LB) medium (10 g/l tryptone, 5 g/l yeast extract, and 10 g/l sodium chloride). The precultured cells were streaked on solid selection medium containing 17 g/l Miller Hilton agar (Sigma, USA), 0.4 g/l L-arabinose, 50 μg/ml ampicillin, and 0–200 μg/ml kanamycin and were incubated overnight at 37°C.

Construction of FucT2 Mutant Library

To construct a primary FucT2 mutant library, the gene coding for FucT2 was amplified with pSel2-FucT2 I FW and BW primers using a GeneMorph II Random Mutagenesis Kit (Agilent Technologies, USA) according to the manufacturer’s instructions. The resulting PCR products were ligated with the pSel2 plasmid to construct an intermediate plasmid, and additional mutations were introduced using a JBS DNA-Shuffling Kit (Jena Bioscience, Germany), as specified by the manufacturer. Briefly, the primary FucT2 mutant library present in the intermediate plasmid was amplified using Pfu polymerase (Elpis Biotech, Korea). The products were purified using a gel-prep kit (Elpis-Biotech) and digested with DNase I. The digested DNA fragments were reassembled using Taq polymerase (Elpis-Biotech) without primers, and reassembled FucT2 was amplified using pSel2-FucT2 I FW and BW primers. The amplified FucT2 mutant library was ligated with the pSel2 plasmid to generate pSel2-FucT2mut.

Selection of FucT2 Mutants with Improved Solubility

105–106 E. coli TOP10 cells harboring FucT2 mutant library were plated on solid selection medium containing 17 g/l Miller Hilton agar, 0.4 g/l L-arabinose, 50 μg/ml ampicillin, and 0–200 μg/ml kanamycin and were incubated overnight at 37°C. Kanamycin was added at final concentrations of 10, 25, 50, and 100 μg/ml for the first, second, third, and fourth rounds, respectively. Fifteen large colonies were selected in each round of directed evolution.

Preparation of Proteins

E. coli Top10 strains harboring pSel2-FucT2 or pSel2-FucT2mut were precultured overnight at 37°C and 200 rpm in LB medium. After harvesting the cells, cell pellets were used for inoculation. A batch was cultured in a 250-ml baffled flask containing 50 ml of LB medium and 50 μg/ml ampicillin at 37°C and 200 ×g. The cells were cultivated for 3 h in the absence of an inducer, and then cultivated for an additional 3 h after the addition of 2 g/l L-arabinose. After harvesting the cells, the cell pellets were resuspended in phosphate-buffered saline (pH 7.4) and disrupted using an ultrasonic machine (Sonics & Materials Inc., USA) on ice. The total, soluble, and insoluble fractions of intracellular proteins were prepared as previously described [12].

Analysis of Protein Expression

Protein samples were separated using 12% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. In immunoblot assays, His6-fusion proteins were detected using an anti-polyhistidine antibody (Sigma-Aldrich), as specified by the manufacturer. Band intensities were quantified using densitometry software (GelAnalyzer 19.1, Hungary).

Culture Conditions and Analytical Methods

E. coli ΔL M15 strain [11] harboring pBCGW [22] was used as a host for 2'-FL production. Batch fermentation was performed in a 250-ml baffled flask containing 50 ml of a defined medium [13.5 g/l KH2PO4, 4 g/l (NH4)2HPO4, 1.7 g/l citric acid, 1.4 g/l MgSO4·7H2O, and 10 ml/l trace element solution (10 g/l FeSO4·7H2O, 2.25 g/l ZnSO4·7H2O, 1.0 g/l CuSO4·5H2O, 0.35 g/l MnSO4·H2O, 0.23 g/l Na2B4O7·10H2O, 0.1 g/l (NH4)6Mo7O24·4H2O, and 2.0 g/l CaCl2·2H2O), pH 6.8] with 20 g/l glycerol and 50 μg/ml ampicillin at 37°C and 200 rpm. At the mid-exponential growth phase, isopropyl β-D-1-thiogalactopyranoside (IPTG) and lactose were added at final concentrations of 0.1 mM and 5 g/l, respectively. After IPTG induction, the temperature was increased to 25°C.

Lactose, glycerol, and 2'-FL concentrations were determined using high-performance liquid chromatography (Waters Corporation, USA). Metabolites were separated using a Rezex ROA-Organic Acid H+ column (Phenomenex, USA) in isocratic mode at a constant temperature (50°C) and a flow rate of 0.6 ml/min in 0.01 N H2SO4, and then passed through a refractive index detector (Fig. S1).

Statistical Analysis

Statistical methods were not used to determine sample size. Randomization and blind tests were not performed to evaluate the experimental procedures and results. Each experiment was performed in triplicate. Numerical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). The Student’s t-test was used to determine numerical significance. The results were considered significant when p < 0.05.

Results

Expression of an Insoluble FucT2-KanR Fusion Protein Comprising FucT2 and Kanamycin Resistance Protein

To construct an expression plasmid (pSel2-FucT2) for the fusion protein (FucT2-KanR) consisting of FucT2 and kanamycin resistance protein (KanR), the coding sequence of FucT2 was cloned into the pSel2 plasmid containing the PBAD promoter, in which protein expression was induced by adding L-arabinose. The recombinant E. coli Top10 harboring pSel2 and pSel2-FucT2 was grown at 37°C for 3 h in the presence of 2 g/l L-arabinose, and the total and soluble protein fractions were analyzed by Western blotting. Most FucT2-KanR were not expressed as soluble forms (Fig. 2A). Densitometric analysis showed only 10% FucT2-KanR expression in the soluble form.

Figure 2. The loss of Kan resistance owing to FucT2 insolubility. (A) Western blot analysis was used to confirm the expression of FucT2-KanR. Cell lysates were prepared from recombinant E. coli Top10 containing pSel2 and pSel2-FucT2 and fractionated into total (T) and soluble (S) fractions. (B, C) Recombinant E. coli Top10 containing pSel2 (B) and pSel2-FucT2 (C) were streaked on selection medium containing various concentrations of Kan.

To determine the minimum concentration of kanamycin that completely inhibits the growth of the E. coli strain expressing FucT2-KanR, E. coli Top10 harboring pSel2 and pSel2-FucT2 was grown on solid medium containing various concentrations of kanamycin. In the DNA sequences of the pSel2 plasmid, frameshift mutations were introduced in the coding regions of KanR. Consequently, E. coli Top10 harboring pSel2 was not able to grow in medium containing 5–100 μg/ml kanamycin (Fig. 2B). Insertion of the coding sequence of FucT2 into the pSel2 plasmid resulted in the formation of FucT2-KanR that was designed to counter the effects of frameshift mutations (Fig. S2). Accordingly, the FucT2-KanR fusion protein would catalyze the conversion of kanamycin into an inactive form if it were expressed in a soluble form. However, the growth of E. coli Top10 expressing FucT2-KanR was not detected in the kanamycin-containing medium to be tested (Fig. 2C). This result indicates that the expression of soluble FucT2-KanR was too low to confer resistance to kanamycin, even at a low kanamycin concentration (5 μg/ml). Therefore, 10 μg/ml was selected as the basal concentration for further experiments on the directed evolution of FucT2.

Construction of a FucT2 Mutant Library and Selection of FucT2 Mutants

In this study, a combination of error-prone PCR and DNA shuffling was used to obtain FucT2 variants with improved solubility. A primary FucT2 mutant library constructed via error-prone PCR (Fig. S3B) was re-amplified using Pfu polymerase (lane 2, Fig. S3C). After digesting the resulting PCR products with DNase I (lane 3, Fig. S3C), DNA fragments were reassembled into a full-length gene in the absence of primers (lane 4, Fig. S3C). The 903-bp DNA fragments containing FucT2 mutant libraries were amplified with pSel2-FucT2 I FW and BW primers and then ligated into the pSel2 plasmid to construct pSel2-FucT2mut (lane 5, Fig. S3C).

Fifteen large colonies of E. coli Top10 harboring pSel2-FucT2mut and grown on solid medium containing 10 μg/ml kanamycin were selected, and DNA sequences of the gene coding for FucT2 mutants were analyzed. Among various FucT2 mutants, we decided to focus on full-length variants, excluding mutants with frameshift, truncation, and/or overlapping. Based on this criterion, two FucT2 mutants were selected from the first round of the overall process represented in Fig. 1 and mixed at the same ratio for use as the template for the next round of directed evolution and selection. Finally, 15 FucT2 mutants were collected after four rounds of the overall process (Table 2).

Table 2 . A list of FucT2 mutants isolated from five rounds of directed evolution process..

aDel: amino acid deletion.



Soluble Expression of FucT2 via KanR-Mediated Directed Evolution

F#1-5, F#1-13, and F#2-11 mutants were selected from the first and second rounds of directed evolution. Before measuring the expression of WT FucT2 and its mutants selected via directed evolution using KanR as a biosensor motif, colony-forming units (CFUs) of E. coli Top10 strains expressing WT FucT2 and its three mutants (F#1-5, F#1-13, and F#2-11) were compared on LB medium with and without 25 μg/ml kanamycin. The CFUs of all strains were almost identical in LB medium without kanamycin (Fig. 3A). While colony formation by E. coli strains harboring the empty plasmid (pSel2) and pSel2-FucT2 was not observed on LB medium containing kanamycin, E. coli strains expressing F#1-5, F#1-13, and F#2-11 mutants were able to grow in the presence of 25 μg/ml kanamycin (Fig. 3A). Notably, CFUs of E. coli strain expressing the F#2-11 mutant, which were isolated from the second round of directed evolution, were much higher than those of E. coli strains expressing F#1-5 and F#1-13 mutants. This result indicated that the kanamycin resistance potential of FucT2-KanR containing F#1-5 or F#1-13 mutants was further enhanced via the second round of directed evolution.

Figure 3. Validation of KanR-mediated directed evolution for improving the expression of soluble FucT2. (A) Recombinant E. coli Top10 expressing wild-type (WT) FucT2 and its mutants (F#1-5, F#1-13, and F#2-11) were grown on selection medium with and without 25 μg/ml Kan. (B) Western blot analysis was used to confirm FucT2-KanR expression. Cell lysates were prepared from recombinant E. coli Top10 expressing WT FucT2 and its mutants, and divided into total (T) and soluble (S) fractions. (C) Comparison of relative expression of soluble FucT2-KanR detected in Fig. 3B.

Next, we evaluated whether the expression of soluble FucT2 could be enhanced via KanR-mediated directed evolution. Although total expression of the F#2-11 mutant was slightly lower than that of the WT FucT2, and F#1-5 and F#1-13 mutants, the expression of soluble FucT2-KanR by the F#1-5, F#1-13, and F#2-11 mutants was significantly higher than that by the WT (Fig. 3B). The decrease in total expression level of the F#2-11 mutant is likely due to the dynamic transtriptional response of E. coli to the soluble property of the F#2-11 mutant. This result is consistent with a previous study which reported that expression levels of genes involved in protein synthetic pathway were altered due to the change of expression level of inclusion bodies [23]. Analysis of the band intensities by Western blotting showed that the level of soluble FucT2-KanR produced in the presence of F#1-5, F#1-13, and F#2-11 was approximately 3-fold greater than that by the WT (Fig. 3C). Therefore, evolutionary engineering of FucT2 using KanR as a phenotypical reporter successfully enhanced the expression of soluble FucT2.

Enhanced Production of 2'-FL by Engineered E. coli Expressing FucT2 Mutants with Improved Solubility

An engineered E. coli strain BL21star (DE3) ΔL M15 harboring pBCGW (ΔL M15 pBCGW) was previously constructed for de novo production of 2'-FL [11]. Specifically, genes coding for enzymes involved in producing GDP-L-fucose (a precursor of 2'-FL) were overexpressed along with attenuation of the lac operon to redirect carbon flux from lactose to 2'-FL. A previous study reported that the ΔL M15 pBCGW strain expressing WT FucT2 produced 0.16 g/l 2'-FL with a yield of 0.091 g 2'-FL/g lactose [11]. Therefore, we decided to evaluate whether expression of the four FucT2 mutants (F#3-1, F#3-9, F#4-6, and F#4-19) from the third and fourth rounds of KanR-mediated directed evolution, in addition to those from the first and second rounds (F#1-5, F#1-13, and F# 2-11) in the ΔL M15 pBCGW strain, could enhance 2'-FL production. Before comparing 2'-FL production, we analyzed total and soluble expression of the WT FucT2 and its mutant in the absence of KanR fusion. The expression level of soluble FucT2 by the mutants was higher than that by the WT FucT2 in the absence of KanR (Fig. S4). Notably, we observed efficient 2'-FL production by E. coli strains expressing F#1-5, F#2-11, and F#3-1 mutants (Fig. 4). The cell growth patterns of all E. coli strains were almost identical (data not shown). The ΔL M15 pBCGW strains expressing F#1-5, F#2-11, and F#3-1 mutants were able to produce 0.27–0.31 g/l 2'-FL with a yield of 0.17–0.22 g 2'-FL/g lactose, showing 1.46–1.72- and 1.12–1.51-fold increases in the titer and yield, respectively, when compared to those of the control strain expressing WT FucT2. Collectively, the expression of FucT2 mutants evolved using KanR as the phenotypical reporter led to a significant increase in the production titer and yield of 2'-FL in E. coli.

Figure 4. Comparison of 2'-FL production in engineered E. coli strains expressing wild-type (WT) FucT2 (A) and F#1-5 (B), F#2-11 (C), and F#3-1 (D) mutants. At the mid-exponential growth phase, IPTG and lactose were added at final concentrations of 0.1 mM and 5 g/l, respectively. Results are the mean of duplicate experiments and error bars indicate standard deviation.

Discussion

α-1,2-Fucosyltransferase is the rate-limiting enzyme in E. coli-based production of 2'-FL [11]. Therefore, in this study, we aimed to enhance its solubility and functional expression of 2'-FL. The efficient construction of desired mutants via rational design is not possible without prior knowledge of the structure and mechanism of action of the target enzymes [24]. Given the absence of structural information on FucT2, directed evolution was used to improve the expression of soluble FucT2.

The overall process of directed evolution consists of generating a mutant library and high-throughput screening and/or selection (HTSS). Although mutant libraries with controllable numbers of mutations can be generated via modern mutagenesis techniques, such as error-prone PCR and DNA shuffling, the real bottleneck for solubility engineering lies in establishing HTSS for mutant isolation [25]. Using a biosensor of protein solubility may overcome such bottlenecks, thereby increasing the probability of selecting desired mutants. A typical biosensor of protein solubility consists of target and phenotypical reporter proteins [26]. Since these two are expressed as a fusion protein, the activity of the reporter is affected by the solubility of the target protein. Chloramphenicol acetyltransferase (CAT), which confers resistance to chloramphenicol, is a frequently used reporter protein owing to its easily detectable enzymatic activity [27]. Cells expressing insoluble and/or unstable proteins fused to CAT were unable to grow in the presence of chloramphenicol, whereas mutants with improved solubility and/or stability could be isolated from solid medium containing chloramphenicol. Examples of successful applications of CAT-based biosensors include isolation of mitochondrial Acytochrome P450 [28], imidazole glycerol phosphate synthase [29], and interleukin-15 [30] mutants with improved solubility and/or stability. In addition to CAT, green fluorescent protein (GFP) has been used as a phenotypical reporter protein. In recent studies, the solubility and/or stability of L-serine/L-threonine exchanger [31] and esterase [32] were significantly improved via the GFP-mediated directed evolution coupled with fluorescence size-exclusion chromatography analysis and fluorescence-activated cell sorting, respectively. In this system, variants with high levels of soluble protein expression can confer GFP with strong fluorescence, whereas low stability and/or solubility of target proteins results in improper folding of GFP which in turn lead to a decrease in the intensity of fluorescence.

For the biosensor with CAT to be viable, the activity of CAT should be solely dependent on FucT2 solubility. However, CAT activity in the fusion protein is dependent on its quaternary structure in addition to the solubility of target proteins because the homotrimeric CAT is catalytically active only as a trimer [33]. Therefore, KanR was employed in this study as an alternative phenotypic reporter. Although KanR thermodynamically favors dimers of identical subunits, dimerization does not affect its activity [34].

We noted that a single round of the overall directed evolution process enabled the expression of soluble FucT2, which resulted in a significant increase in 2'-FL production. However, the increase in FucT2 activity was not proportional to the extent of FucT2 solubility. Although the mechanism remains to be investigated, we hypothesize that one of the reasons for this might be due to the activity-solubility trade-offs, or rather, the negative correlation between activity and solubility [35, 36]. Since amino acids in enzymes have multiple roles, the adjustment of one physical parameter could influence other properties [37, 38]. Among seven FucT2 mutants with improved solubility, only three (F#1-5, F#1-13, and F# 2-11) exhibited higher activity than that of the WT FucT when expressed in ΔL M15 pBCGW strain (Fig. S5). In addition, the activity of KanR was not directly proportional to the expression level of soluble FucT2-KanR by the mutants. These results are consistent with those of previous studies that reported a decrease in enzyme activity of the mutants with improved solubility and/or stability [37-39]. In our ongoing research, we are striving to identify the key mutations that play crucial roles in solubility enhancement and/or mutations that enhance solubility without negatively affecting activity. The FucT2 structure predicted using AlphaFold [40], an artificial intelligence method for predicting protein structures, showed that the key mutation sites (V33, G84, D120, and I287) were present on the surface of FucT2 (Fig. S6). A previous study reported that hydrophobic amino acids on the surface of recombinant proteins played an important role in the formation of inclusion body [41]. Therefore, we speculated that the V33M, G84R, D120N, and I287M mutations enhanced expression level of soluble FucT2 by decreasing formation of inclusion body.

In conclusion, in this study, we aimed to enhance the expression of soluble FucT2 via directed evolution for the efficient production of 2'-FL. To this end, KanR was employed in this study as a phenotypic reporter, whose activity is affected by the solubility of FucT2. Three FucT2 mutants (F#1-5, #F2-11, and F#3-1) with improved solubility and activity were successfully isolated. Finally, ΔL M15 pBCGW strain expressing F#1-5, #F2-11, and F#3-1 produced 0.27–0.31 g/l 2'-FL, showing a 1.46–1.72 fold increase in 2'-FL titer, compared to those of the control strain. Therefore, our approach could be applied to other biotransformation processes that include highly unstable and insoluble enzymes.

Supplemental Materials

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2017R1A6A1A03015642 and NRF-2020R1A2C2101964). This research was also supported by the Chung-Ang University Graduate Research Scholarship (Academic Scholarship for College of Biotechnology and Natural Resources) in 2022.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

Fig 1.

Figure 1.A schematic diagram representing overall process of directed evolution. FucT2 mutant libraries were generated via a combination of error-prone PCR and DNA shuffling. The expression of the fusion protein (FucT2-KanR) consisting of FucT2 and kanamycin (Kan) resistance protein (KanR) was under the transcriptional control of the PBAD promoter. The amino acid sequence of the linker was KSAAGT. Kan-resistant E. coli Top10 cells expressing FucT2-KanR were isolated from solid LB medium containing 2 g/l L-arabinose and 10–200 μg/ml Kan. Finally, the solubility and activity of FucT2 mutants were characterized, or they were used as substrates for the next round of evolution.
Journal of Microbiology and Biotechnology 2022; 32: 1471-1478https://doi.org/10.4014/jmb.2209.09018

Fig 2.

Figure 2.The loss of Kan resistance owing to FucT2 insolubility. (A) Western blot analysis was used to confirm the expression of FucT2-KanR. Cell lysates were prepared from recombinant E. coli Top10 containing pSel2 and pSel2-FucT2 and fractionated into total (T) and soluble (S) fractions. (B, C) Recombinant E. coli Top10 containing pSel2 (B) and pSel2-FucT2 (C) were streaked on selection medium containing various concentrations of Kan.
Journal of Microbiology and Biotechnology 2022; 32: 1471-1478https://doi.org/10.4014/jmb.2209.09018

Fig 3.

Figure 3.Validation of KanR-mediated directed evolution for improving the expression of soluble FucT2. (A) Recombinant E. coli Top10 expressing wild-type (WT) FucT2 and its mutants (F#1-5, F#1-13, and F#2-11) were grown on selection medium with and without 25 μg/ml Kan. (B) Western blot analysis was used to confirm FucT2-KanR expression. Cell lysates were prepared from recombinant E. coli Top10 expressing WT FucT2 and its mutants, and divided into total (T) and soluble (S) fractions. (C) Comparison of relative expression of soluble FucT2-KanR detected in Fig. 3B.
Journal of Microbiology and Biotechnology 2022; 32: 1471-1478https://doi.org/10.4014/jmb.2209.09018

Fig 4.

Figure 4.Comparison of 2'-FL production in engineered E. coli strains expressing wild-type (WT) FucT2 (A) and F#1-5 (B), F#2-11 (C), and F#3-1 (D) mutants. At the mid-exponential growth phase, IPTG and lactose were added at final concentrations of 0.1 mM and 5 g/l, respectively. Results are the mean of duplicate experiments and error bars indicate standard deviation.
Journal of Microbiology and Biotechnology 2022; 32: 1471-1478https://doi.org/10.4014/jmb.2209.09018

Table 1 . Escherichia coli strains and plasmids used in this study..

NameDescriptionReference
E. coli
TOP10F mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupGInvitrogen (USA)
ΔL M15BL21 star (DE3) ΔlacZYA Tn7::lacZΔM15[11]
Plasmids
pSel2PBAD promoter-KanR expression system, ColEI origin, AmpR[42]
pSel2-FucT2pSel2 + wild type FucT2This study
pSel2-FucT2mutpSel2 + FucT2 mutantsThis study
pColAduet-1Two T7 promoters, ColA origin, KanRNovagen (Germany)
pColAduet-FucT2pColAduet + wild type FucT2 from H. pyloriAP Technology (Republic of Korea)
pColAduet-FucT2mutpColAduet + FucT2 mutantsThis study

Table 2 . A list of FucT2 mutants isolated from five rounds of directed evolution process..

aDel: amino acid deletion.


References

  1. Bode L. 2012. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22: 1147-1162.
    Pubmed KoreaMed CrossRef
  2. Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, et al. 2006. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediat. Res. 59: 377-382.
    Pubmed CrossRef
  3. Thurl S, Munzert M, Henker J, Boehm G, Mller-Werner B, Jelinek J, et al. 2010. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. Br. J. Nutr. 104: 1261-1271.
    Pubmed CrossRef
  4. Smith-Brown P, Morrison M, Krause L, Davies PSW. 2016. Mothers secretor status affects development of childrens microbiota composition and function: a pilot study. PLoS One 11: e0161211.
    Pubmed KoreaMed CrossRef
  5. Han NS, Kim TJ, Park YC, Kim J, Seo JH. 2012. Biotechnological production of human milk oligosaccharides. Biotechnol. Adv. 30: 1268-1278.
    Pubmed CrossRef
  6. Li C, Wu M, Gao X, Zhu ZL, Li Y, Lu FP, et al. 2020. Efficient biosynthesis of 2'-fucosyllactose using an in vitro multienzyme cascade. J. Agr. Food Chem. 68: 10763-10771.
    Pubmed CrossRef
  7. Lee HJ, Shin DJ, Han K, Chin YW, Park JP, Park K, et al. 2022. Simultaneous production of 2'-fucosyllactose and difucosyllactose by engineered Escherichia coli with high secretion efficiency. Biotechnol. J. 17: e2100629.
    Pubmed CrossRef
  8. Shin J, Jin YS, Park YC, Park JB, Lee YO, Kim SK, et al. 2021. Enhancing acid tolerance of Escherichia coli via viroporin-mediated export of protons and its application for efficient whole-cell biotransformation. Metab. Eng. 67: 277-284.
    Pubmed CrossRef
  9. Yu S, Liu JJ, Yun EJ, Kwak S, Kim KH, Jin YS. 2018. Production of a human milk oligosaccharide 2'-fucosyllactose by metabolically engineered Saccharomyces cerevisiae. Microb. Cell Fact. 17: 101.
    Pubmed KoreaMed CrossRef
  10. Liu TW, Ito H, Chiba Y, Kubota T, Sato T, Narimatsu H. 2011. Functional expression of L-fucokinase/guanosine 5'-diphosphate-Lfucose pyrophosphorylase from Bacteroides fragilis in Saccharomyces cerevisiae for the production of nucleotide sugars from exogenous monosaccharides. Glycobiology 21: 1228-1236.
    Pubmed CrossRef
  11. Chin YW, Kim JY, Lee WH, Seo JH. 2015. Enhanced production of 2'-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase. J. Biotechnol. 210: 107-115.
    Pubmed CrossRef
  12. Park Y, Shin J, Yang J, Kim H, Jung Y, Oh H, et al. 2020. Plasmid display for stabilization of enzymes inside the cell to improve wholecell biotransformation efficiency. Front. Bioeng. Biotechnol. 7: 444.
    Pubmed KoreaMed CrossRef
  13. Ren J, Hwang S, Shen J, Kim H, Kim H, Kim J, et al. 2022. Enhancement of the solubility of recombinant proteins by fusion with a short-disordered peptide. J. Microbiol. 60: 960-967.
    Pubmed CrossRef
  14. Mamipour M, Yousefi M, Hasanzadeh M. 2017. An overview on molecular chaperones enhancing solubility of expressed recombinant proteins with correct folding. Int. J. Biol. Macromol. 102: 367-375.
    Pubmed KoreaMed CrossRef
  15. Wang T, Badran AH, Huang TP, Liu DR. 2018. Continuous directed evolution of proteins with improved soluble expression. Nat. Chem. Biol. 14: 972-980.
    Pubmed KoreaMed CrossRef
  16. Reyes LH, Cardona C, Pimentel L, Rodriguez-Lopez A, Almeciga-Diaz CJ. 2017. Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches. Sci. Rep. 7: 5844.
    Pubmed KoreaMed CrossRef
  17. Han X, Ning W, Ma X, Wang X, Zhou K. 2020. Improving protein solubility and activity by introducing small peptide tags designed with machine learning models. Metab. Eng. Commun. 11: e00138.
    Pubmed KoreaMed CrossRef
  18. Kim C, Park M, Yang J, Shin J, Park YC, Kim SK, et al. 2021. Inducible plasmid display system for high-throughput selection of proteins with improved solubility. J. Biotechnol. 329: 143-150.
    Pubmed CrossRef
  19. Wang H, Wang L, Zhong BH, Dai ZJ. 2022. Protein splicing of inteins: a powerful tool in synthetic biology. Front. Bioeng. Biotechnol. 10: 810180.
    Pubmed KoreaMed CrossRef
  20. ang J, Kim N, Park W, Chun J, Kim S, Shin J, et al. 2022. Optimization of protein trans-splicing in an inducible plasmid display system for high-throughput screening and selection of soluble proteins. Enzyme Microb. Technol. 153: 109914.
    Pubmed CrossRef
  21. Li CK, Wen AY, Shen BC, Lu J, Huang Y, Chang YC. 2011. FastCloning: a highly simplified, purification-free, sequence- and ligationindependent PCR cloning method. BMC Biotechnol. 11: 92.
    Pubmed KoreaMed CrossRef
  22. Lee WH, Han NS, Park YC, Seo JH. 2009. Modulation of guanosine 5'-diphosphate-D-mannose metabolism in recombinant Escherichia coli for production of guanosine 5'-diphosphate-L-fucose. Bioresour. Technol. 100: 6143-6148.
    Pubmed CrossRef
  23. Baig F, Fernando LP, Salazar MA, Powell RR, Bruce TF, Harcum SW. 2014. Dynamic transcriptional response of Escherichia coli to inclusion body formation. Biotechnol. Bioeng. 111: 980-999.
    Pubmed KoreaMed CrossRef
  24. Packer MS, Liu DR. 2015. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16: 379-394.
    Pubmed CrossRef
  25. Hart DJ, Tarendeau F. 2006. Combinatorial library approaches for improving soluble protein expression in Escherichia coli. Acta Crystallogr. D 62: 19-26.
    Pubmed CrossRef
  26. Ren C, Wen X, Mencius J, Quan S. 2019. Selection and screening strategies in directed evolution to improve protein stability. Bioresour. Bioprocess 6: 53.
    CrossRef
  27. Daunert S, Barrett G, Feliciano JS, Shetty RS, Shrestha S, Smith-Spencer W. 2000. Genetically engineered whale-cell sensing systems: coupling biological recognition with reporter genes. Chem. Rev. 100: 2705-2738.
    Pubmed CrossRef
  28. Janocha S, Bichet A, Zollner A, Bernhardt R. 2011. Substitution of lysine with glutamic acid at position 193 in bovine CYP11A1 significantly affects protein oligomerization and solubility but not enzymatic activity. Biochim. Biophys. Acta 1814: 126-131.
    Pubmed CrossRef
  29. Seitz T, Bocola M, Claren J, Sterner R. 2007. Stabilisation of a (βα)8-barrel protein designed from identical half barrels. J. Mol. Biol. 372: 114-129.
    Pubmed CrossRef
  30. Behar G, Sole V, Defontaine A, Maillasson M, Quemener A, Jacques Y, et al. 2011. Evolution of interleukin-15 for higher E. coli expression and solubility. Protein Eng. Des. Sel. 24: 283-290.
    Pubmed CrossRef
  31. Rodriguez-Banqueri A, Errasti-Murugarren E, Bartoccioni P, Kowalczyk L, Peralvarez-Marin A, Palacin M, et al. 2016. Stabilization of a prokaryotic LAT transporter by random mutagenesis. J. Gen. Physiol. 147: 353-368.
    Pubmed KoreaMed CrossRef
  32. Mo HM, Xu Y, Yu XW. 2018. Improved soluble expression and catalytic activity of a thermostable esterase using a high-throughput screening system based on a split-GFP assembly. J. Agr. Food Chem. 66: 12756-12764.
    Pubmed CrossRef
  33. Biswas T, Houghton JL, Garneau-Tsodikova S, Tsodikov OV. 2012. The structural basis for substrate versatility of chloramphenicol acetyltransferase CATI. Protein Sci. 21: 520-530.
    Pubmed KoreaMed CrossRef
  34. Wright GD, Thompson PR. 1999. Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Front. Biosci. 4: D9-21.
    CrossRef
  35. Tokuriki N, Stricher F, Serrano L, Tawfik DS. 2008. How protein stability and new functions trade off. PLoS Comput. Biol. 4: e1000002.
    Pubmed KoreaMed CrossRef
  36. Wang XJ, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320: 85-95.
    Pubmed CrossRef
  37. DePristo MA, Weinreich DM, Hartl DL. 2005. Missense meanderings in sequence space: a biophysical view of protein evolution. Nat. Rev. Genet. 6: 678-687.
    Pubmed CrossRef
  38. Studer RA, Christin PA, Williams MA, Orengo CA. 2014. Stability-activity tradeoffs constrain the adaptive evolution of RubisCO. Proc. Natl. Acad. Sci. USA 111: 2223-2228.
    Pubmed KoreaMed CrossRef
  39. Tokuriki N, Tawfik DS. 2009. Stability effects of mutations and protein evolvability. Curr. Opin. Struc. Biol. 19: 596-604.
    Pubmed CrossRef
  40. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596: 583-589.
    Pubmed KoreaMed CrossRef
  41. Jung SY, Park SS. 2008. Improving the expression yield of Candida antarctica lipase B in Escherichia coli by mutagenesis. Biotechnol. Lett. 30: 717-722.
    Pubmed CrossRef
  42. Massey-Gendel E, Zhao A, Boulting G, Kim HY, Balamotis MA, Seligman LM, et al. 2009. Genetic selection system for improving recombinant membrane protein expression in E. coli. Protein Sci. 18: 372-383.
    Pubmed KoreaMed CrossRef